MEASURING ELECTRO-CHEMICAL PROPERTIES OF FLOWABLE MATERIALS

    公开(公告)号:WO2023086454A1

    公开(公告)日:2023-05-19

    申请号:PCT/US2022/049518

    申请日:2022-11-10

    Abstract: The invention provides an integrated multi-channel battery analyzer including one or more measurement units and accompanying pluggable battery capsules that physically and electrically connect to the measurement unit(s) to obtain multiple measurements simultaneously of electro-chemical properties for flowable materials, e.g., flowable batteries. The battery capsules are in a stacked configuration and include electrical components, e.g., positive and negative electrodes, and positive and negative flow channels through which the positive and negative electrolyte travels, respectively, as well as a separator positioned between the flow channels, and at least one pump. In addition, the battery capsules have a small size as compared to battery capsules known in the art.

    HYDROGENATION OF CANNABIS OIL
    4.
    发明申请
    HYDROGENATION OF CANNABIS OIL 审中-公开
    加油加油

    公开(公告)号:WO2016179581A1

    公开(公告)日:2016-11-10

    申请号:PCT/US2016/031441

    申请日:2016-05-09

    Abstract: The present invention relates to the extraction and hydrogenation of essential oil of a cannabis plant. The invention includes hydrogenated cannabis compounds and compositions, as well as methods of preparation and therapeutic uses for regressing tumors in a cancer patient. The extract can include 9-tetrahydrocannabinoic acid and 9-cannabidiolic acid, and the hydrogenated cannabis oil can include hydrogenated 9-tetrahydrocannabinoic acid, hydrogenated 9-cannabidioc acid and, mixtures and blends thereof.

    Abstract translation: 本发明涉及大麻植物精油的提取和氢化。 本发明包括氢化大麻化合物和组合物,以及用于在癌症患者中回归肿瘤的制备方法和治疗用途。 提取物可以包括9-四氢大麻酚酸和9-大麻脂肪酸,氢化大麻脂油可以包括氢化9-四氢大麻酚,氢化9-大麻脂肪酸及其混合物和混合物。

    PODOCALYXIN AND TRA PROGNOSTIC MARKERS FOR AGGRESSIVE AND METASTATIC CANCER
    9.
    发明申请
    PODOCALYXIN AND TRA PROGNOSTIC MARKERS FOR AGGRESSIVE AND METASTATIC CANCER 审中-公开
    芍药苷和TRA预防标记用于肿瘤和分化癌

    公开(公告)号:WO2014159939A1

    公开(公告)日:2014-10-02

    申请号:PCT/US2014/025489

    申请日:2014-03-13

    Applicant: CUREMETA LLC

    Abstract: The invention relates to systems and methods to detect podocalyxin-expressing and TRA-expressing cancer stem cells or cancer cells with stem cell-like properties in a tissue cell sample obtained from a localized tumor of a patient, and to determine a diagnosis or prognosis of aggressive and metastatic cancer by employing podocalyxin and TRA human stem cell markers as prognostic markers.

    Abstract translation: 本发明涉及在从患者的局部肿瘤获得的组织细胞样品中检测表达表皮脂蛋白和表达TRA的癌症干细胞或具有干细胞样特性的癌细胞的系统和方法,并且确定诊断或预后 通过使用足癣和TRA人干细胞标记作为预后标志物,侵袭性和转移性癌症。

    THERAPY AND METHOD FOR INTRATUMORALLY INTRODUCING CYTOTOXIC T LYMPHOCYTE AND/OR NKT CELL WITH ANTI-TNF AND/OR ANTI-IL-10
    10.
    发明申请
    THERAPY AND METHOD FOR INTRATUMORALLY INTRODUCING CYTOTOXIC T LYMPHOCYTE AND/OR NKT CELL WITH ANTI-TNF AND/OR ANTI-IL-10 审中-公开
    用抗TNF和/或抗IL-10诱导细胞因子T淋巴细胞和/或NKT细胞的治疗和方法

    公开(公告)号:WO2014004809A2

    公开(公告)日:2014-01-03

    申请号:PCT/US2013/048152

    申请日:2013-06-27

    Abstract: The invention relates to therapy and methods of applying the therapy to cancer patients. The invention includes introducing intratumorally cytotoxic T lymphocyte and/or NKT cells, and prior to, coincident with, or following introducing intratumorally the cytotoxic T lymphocyte and/or NKT cells, introducing intratumorally anti-TNF and/or anti-IL-10 to the patient. The cytotoxic T lymphocyte and/or NKT cells can be induced by the intratumoral introduction of immature dendritic cells to the patient. This therapy of the invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients in the absence of radiation therapy.

    Abstract translation: 本发明涉及将治疗应用于癌症患者的疗法和方法。 本发明包括引入瘤内细胞毒性T淋巴细胞和/或NKT细胞,并且在肿瘤内引入肿瘤内的细胞毒性T淋巴细胞和/或NKT细胞之前,在肿瘤内引入肿瘤内抗TNF和/或抗IL-10到 患者。 细胞毒性T淋巴细胞和/或NKT细胞可以通过肿瘤内引入未成熟树突细胞给患者来诱导。 本发明的这种治疗可以有效地在没有放射治疗的情况下回归,减少或消除患者的肿瘤组织中的肿瘤细胞。

Patent Agency Ranking